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ABSTRACT
Protection of biological systems against radiation damage is of paramount importance during
accidental and unavoidable exposure to radiation. Several physico-chemical and biological factors
collectively contribute to the damage caused by radiation and are, therefore, targets for developing
radioprotectors. Work on the development of chemicals capable of protecting biological systems
from radiation damage was initiated nearly six decades ago with cysteine being the first molecule
to be reported. Chemicals capable of scavenging free radicals, inducing oxygen depletion,
antioxidants and modulators of immune response have been some of the radioprotectors
extensively investigated with limited success. Mechanism of action of some chemical
radioprotectors and their combinations have been elucidated, while further understanding is
required in many instances. The present review elaborates on structure-activity relationship of
some of the chemical radioprotectors, their evaluation, and assessment, limitation, and future
prospects.
Keywords:Radioprotectors, radiation damage, chemical radioprotectors, herbal radioprotectors,
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NOMENCLATURE
LET Linear energy transfer
D N A Deoxyribonucleic acid
AET BAminoethylisothiouronium  bromide
hydrobromide
M P G PMercaptopropyonylglycine
M E A Mercaptoethylamine
5-HTP 5-Hydroxy-L-tryptophan
5-HT 5-Hydroxytryptamine
H-342 Hoechst-33342
H-258 Hoechst-33258
2-DG 2-Deoxy-D-glucose
EAT Ehrlich ascites  tumor
B M G Brain malignant glioma
GY GmY
CGY Centi  gray
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LD,,  (30) Lethal dose of radiation at which
50  per cent of the animals die within an
observation period of 30 days
LD,,  (30) Lethal dose of radiation at which
100 per cent of the animals die within an
observation period of 30 days
DRF
DMF
CFU
C S F
L
ILS
NPSH
L%
Dose-reduction factor
Dose-modifying factor
Colony formation unit
Colony-stimulating factor
Leavo
Interleukins
Non-protein sulphydryl
Lethal dose at which 50 per cent of the
animals die within an observation period
of 30 days. This is expressed in milligram
per kilogram bodyweight of experimental
animal
Effective radiation dose at which
50 per cent of the animals show emesis
D M A 5-(4-Methylpiperazin-l-yl)-2-[2’-3,4-
dimethoxyphenyl)-5’-benzimidazolyl]
benzimidazole
TBZ 5-(4-Methylpiperazin-l-yl)-2-[2’{2”-(4-
hydroxy-3-methoxyphenyl)-5”-
benzimidazolyl} -B-benzimidazolyl]
benzimidazole
M E G Mercaptoethylguanidine
GSH Glutathione
a - T M G Tocopherol monoglucoside
1. INTRODUCTION
Development of novel and effective approaches
using non-toxic radioprotectors is of considerable
interest for defence  (nuclear wars), nuclear industries,
radiation accidents, space flight, etc, besides playing
important role in the protection of normal tissues
during radiotherapy of tumors.
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Deleterious effects of radiation on biological
systems develop in a temporal sequence across
various levels of organisation, starting from the
induction of primary lesions in the biomolecules
and structures, eliciting repair processes, leading
to the cell death or transformation responsible for
morbidity, genetic disorder, and cancer. Therefore,
various strategies have been developed to protect
biological systems by interfering in the development
of radiation damage (Fig. 1).
Ionising radiation [particularly, the low linear
energy transfer (LET) radiation] exerts its effect
through the generation of free radicals that destroy
the vital macromolecule (eg, DNA) and structures
such as membranes of the target cell. Following
wholebody exposure to moderate doses (2-5 Gy),
damage to the heamapoetic cells is the major cause
of morbidity, while at higher doses (5-  10 Gy), damage
to the gastrointestinal tract also contributes to the
total effect. Therefore, development of agents, which
reduce the free radical-mediated damage, acts as
enhancers of repair and recovery process, as well
as modifiers of immune system (biological-response
modifiers) has been investigated to rescue the organism
from radiation injury. An ideal radioprotector should
have the following abilities functionally:
(a) Free radical scavenging
(b) Reduce oxidative damage
(c) Facilitate DNA and cellular repair
(d) Immuno-modulation, and
(e) Facilitate repopulation of damaged/affected organs.
From the viewpoint of practical application,
the radioprotector is expected to have the following
capabilities:
(a>
(b)
Cc)
It should offer good protection against both
acute and chronic radiation damage.
It should be suitable for oral administration
and be rapidly absorbed and distributed throughout
the body.
It should not show any significant toxicity,
including those on behaviour.
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Figure 1. Biological response to radiation damage and strategies for protection
(d) Shelf-life should be long, easy handling and
storage.
the chemical radioprotectors with an emphasis on
structure-function relationship has also been highlighted.
(e) It should be readily available and inexpensive. 2. RADIATION INJURY & PROTECTION
The initial stages of radioprotector development,
mostly aminothiol compounds like AET, MPG, MEA,
L-cysteine, glutathione, cysteamine, etc emphasised
on the physico-chemical and radiobiological parameters
(Table 1). Table 2 shows radioprotectors currently
under experimental and clinical investigations.
The efforts, development, and contemporary
status of radioprotectors have been reviewed on
a number of occasions in the past, which have
focused on the nature of compounds, mode of action,
efficacy, and toxicity’“. This paper gives an overview
of the various processes involved in the temporal
and functional development of radiation injury in
biological systems, the models and approaches currently
employed in evaluation. Current status of some of
Injury resulting from the penetration of
biological tissue by ionising radiation is brought
about by the transfer of radiation energy to critical
biological macromolecules (eg, DNA, proteins,
membrane, lipids, etc). The initial chemical injury
can occur in two ways, either directly from the
absorption of radiation energy by the target
macromolecules themselves or indirectly from
diffusible ions and free radicals6  produced by
radiolytic products of water. A cellular water
mol?cule  on irradiation produces hydroxyl radicals
(OH ), hydrated electrots,  hydrogen radicals,
hydroperoxy radicals ( H 02 ), etc. Of these, OH
and solvated electrons ?re  produced in the highest
concentration and OH is considered to be the
most damaging6*7. When target macromolecules
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Table 1. Physico-chemical  and radiobiological properties of some well-known chemical radioprotectors
Cysteine
Cystamine
Structure Molecular weight Dose Biological material DRF Effect Type of radiation Ref.& dose rate No.
NH?-CH-CHa-SH
I
CGGH
NH*-CHr-CH2-S
I
NH2-CH2-CH2-S
Cysteamine SH - CH,  - CHa - NH2
5-Hydroxy-L-
tryptophan (5HTP)
CHz- CH-COOH
;Hz
NH
S-Hydroxytryptamine
(5HT)
CHdHz
AH 1
NH
P-Mercaptopropionyl- CHj  - CH - CONH - CHr-COOH
glycine (MPG) IS H
8-Aminoethyl- NH,-CHr-CH2-S-C=NH
isolhiouroniumbromide I
hydro-bromide (AET) NHz
CONH
I
NH2-  CH-(CH&-CONH-CH
Glutathione I I
COOH CHrSH
I
CHaOH
WR-272 1
NH*-CHr-CH2CH2-NH
I
SP03H2-CH2-CH2
121.20
153.33
77.20
220.20
175.20
163.20
281.04
307.33
232.25
40 ‘wd”Y Male mice 1.19 Survival
50 mg/kg Wister rats 1.79 Survival
150 mgflrg  Rat cerebral cortex 1.30 Degeneration
200 mgkg Male mice
3 mg/  0.5 ml Female mice
20 ‘w&J Male mice
0.45 rnM/kg Mouse cells
Ehrlich ascites
tumor cell lines
400 mgkg Male mice
1.20 Survival
Survival
Survival
1  2. to  Reduced frequency
1.34 of polychromaticerythrocytes
Average DNA
content per cell
@b-y;  0.35 Gyls 104
x-ray; 6.75 Gy 108
@to-y;  0.24 Gyis 111
x-ray; 20 Gy 112
1.75 Survival ‘3’cs-y;  0.0195 Gy/s  113
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Table  2 .  Radioprotectors  under  experimental  and c l in ical  invest igat ions
Compound Mode of action Efficacy Toxici ty Ref.  No.
Alcohols
Dimethyl  sulphoxide
A E T
Mercaptoethylamine
Serotonin
WR-272 1
Vitamin E
DNA-Hoechst
Diltiazem
Bacterial endotoxin
Cytokines
Prostaglandins
Deoxyspergualin
Herbal extracts
S-HTP
S-HTP + AET
Radical  scavenging
Radical  scavenging
Radical  scavenging
Radical  scavenging
Local tissue anoxia
Radical  scavenging
Response modifier
Oxidative damage
Inactivation of free and DNA
radicals
Calcium antagonist
Immunomodulat ion
Modify biological response
Modification of membrane
receptors
Immunomodulat ion
Radical scavenging,
antioxidant, and
immunomodula t ion
Radical scavenging T
Radical scavenging, membrane
receptor modulation
Immunomodulat ion
Good
Good
Polysaccharides, glucan Moderate
a-TMG Oxidative damage Moderate
Good High 114
Good High 115
Good High 61,116,117
Good High 118
Good High 119
Good High/  moderate 120-124
Low-moderate L o w 125-126
Good L o w 12, 13,37,38
Moderate High 17,48,49
Moderate High 127
Moderate High 128
Low Moderate 129
Moderate Low 129
Moderate Low 82-90,93-95
L o w
Low
High
Low
18,58
16, SO-57,60,65,
130-135
128
34,35
are irradiated directly or react with high energy
free radicals and their intermediates, the targets
themselves become ionised or transformed into
the free radicals. The end result is disruption of
molecular structure and function, leading to altered
cell metabolism and injury.
Radiation-induced damages in DNA in cellular
milieu include damaged purine and pyrimidine
bases, single-and double-strand breaks, removal
of bases and cross-linking of DNA with adjacent
protein molecules. These changes, depending on
their type and extent, are expressed functionally
in a variety of ways, including cell death. Radiation
through free radicals can produce a variety of
alterations in membrane lipids and associated
proteins. This can also contribute significantly
to altered cellular function and cell deaths-lo.
Further, radiation effects that lead to incapacitation
and performance decrement, appear to occur very
rapidly and are not related to DNA damage. Some
of these are related to radiation-induced membrane
damage. Lipid peroxidation takes place after
irradiation or free-radical attackg,lO.  This leads
to the production of short chain fatty acyl derivatives,
lipid-lipid cross-linking as well as protein-protein
and lipid-protein cross-linking, oxidation of
accessible amino acids, protein denaturation, and
scission of disulphide bonds in proteins. Functionally,
these changes can be expressed as altered membrane
fluidity and permeability, which could trigger
the release of potent physiological mediators.
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Activity of enzymes associated with these membranes
may be altered by the disruption of lipid
microenvironment and protein structure.
The radiation-induced damages occur as a sequence
of events traversing a time scale from a picosecond
to few hours. Earliest time is that stage at which
radioprotection begins to function. Radioprotecting
molecules compete with free radicals so that radiation-
induced damage to cellular biomacromolecules are
hindered. Between 10.’  and 10m3  s, the reactions of
most water-produced free radicals are essentially
complete”.
At this time (10s6  s), radioprotectors begin
to repair chemical lesions in target molecules by
reducing oxidative damage induced by the free
radicals. Between loo  s and lo4 s, endogenous
enzyme systems come into play to remove the
more slowly reacting products of water radiolysis
and to repair the chemical lesions produced in
cellular macromolecules*O.
3. SCREENING & ASSESSMENT OF
RADIOPROTECTORS
A number of in vitro as well as in vivo systems
have been extensively used for screening potential
radioprotectors. While wholebody-irradiated lower
mammals (mice and rats) have been the choice
models for evaluating the efficacy as well as
toxicity at the systemic level, studies on the
mechanisms of action have been invariably carried
out using established cell lines of human, murine,
and rodent origin.
3.1 In vitro Studies
A great deal of work on radioprotection in
vitro has been carried out using monolayer cultures
of transformed, but non-malignant cells (eg,
fibroblast) as well as transformed (eg, tumor)
cells. The efficacy of radiomodifiers is assessed
by evaluating their ability to enhance the degree
of survival’2*‘3 in an irradiated cell population
using the macrocolony assay14.  Effects on the
proliferation of irradiated cells have also been
used as assay parameters in vitro.
3.2 In viva Studies
Potential radioprotectors are screened for their
effectiveness by studying the animal survival against
lethal dose as end-point. Some of the reasons for
choosing mice are:
(i) They are relatively inexpensive
(ii) They are housed with moderate space requirement
(iii)They are susceptible to radiation damage and
protection
(iv)They are easy to handle
(v) They are available as standardised strains in
large numbers with known radiosensitivity index
for different strainsi5-I’.
To determine the general applicability of a
particular radioprotector and to facilitate the
extrapolation to human subjects, it is desirable to
demonstrate protection over a range of species like
murine, rodents, canine, and primates. However,
tolerance, toxicity, and effectiveness vary with animal
species and are influenced by the strain, sex, age,
and general condition of the animal.
The routes of administration, eg, intravenous
(i.v.), intraperitoneal (i.p.), intramuscular (im.) and
oral (o), markedly affect the protective action and
toxicity of the compound. Intravenous route helps
in rapid distribution of drug, but toxic reactions
are more common. In general, oral administration
is less effective than intraperitoneal or intramuscular
administration, due to poor absorption and breakdown
of the drug by the acid in the stomach, digestive
enzymes, intestinal flora, or metabolism in the liver.
The effectiveness of a potential radioprotector
is always evaluated prior to its use in combination
with radiation. Generally, the LD,, (dose that produces
lethality in 50  per cent of the animals) is obtained
in the animal model to be tested.
4. DOSE, DOSE RATE, QUALITY OF
RADIATION & PRE-EXPOSURE TIME
The other factors that influence the observed
effects are the type of radiation, absorbed dose,
dose rate, and the rate of availability of radioprotectors’*.
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Lethal dose varies with the strain of mice.
The LD,, of radiation can vary from 7 Gy to 10
Gy depending on the strain. A dose of 4 Gy is
generally considered sublethal. Most commonly,
in vivo radioprotection studies are performed at
radiation doses in the range LD,, (30) or LD,,,
(30). In general, radiation dose rates vary from
40-200 cGy/min. Much of the currently available
information on radioprotectors has been on the
low linear energy transfer (LET) radiation like
x-rays or y-rays.
The time interval between radioprotector
administration and maximum protection varies
markedly from one compound to another. Optimum
pre-exposure time must be determined for each
compound. For most radioprotectors, maximum
protection is achieved when administered between
15 min to 60 min before irradiationlg.
5. EVALU&TION  CRITERIA
The magnitude of chemical protection against
radiation damage is most commonly assessed
either by comparing percentage survival between
the treated and the control groups at a selected
lethal radiation dose, or by computing a dose-
reduction factor (DRF) for the drug under study.
Percentage survival requires fewer animals and
is more easily determined than DRF. To determine
the DRF, groups of treated and control animals
are exposed to several levels of radiation and
observed for survival from day 1 to day 30. The
LD,, of radiation is determined for the control
group (D,) and the protected group (D,). The
DRF is computed1g  as D,/D,.
5.1 Endogenous Spleen Counts
This method is based on the observation that
recovery from radiation injury is accompanied
by the formation of macroscopically identifiable
nodules in the spleen, the number of which is
inversely related to radiation dose. Heamopoetic
radiation injury is linked to blood cell development.
All of the mature elements of the blood are
ultimately derived from bone marrow pluripotent
stem cells20.
Following even low doses of radiation,
stem cell and progenitor cell numbers are
significantly reduced and the potential to generate
new heamopoetic elements is compromised.
Heamopoetic cell survival, proliferation, and
differentiation have now clearly been
demonstrated to be regulated by cytokines,
specifically known as colony-stimulating factor
(CSF), interleukins,  and poetins. When
radioprotectors are incorporated prior to radiation
exposure, endogenous spleen counts have been
found to increase. Different immunomodulators
influence the survival-enhancing effect. That
is how their protective and therapeutic effects
in irradiated animals have been obtained.
6. RELEVANCE OF FUNCTIONAL
GROUPS IN RADIOPROTECTION
Radioprotection under consideration can be
achieved by chemical and biological means. Different
theories that have been propounded are:
(a) Radical scavenging
(b) Hydrogen donation
(c) Mixed disulphide formation
(d) Release of endogenous radioprotectors
(e) Biochemical shock
(f) Hypoxia
(g) Target stabilisation.
Whether it is a chemical or a biological
radioprotector, structure-activity relationship has
gained importance since 1940. The general rule,
that has emerged from intensive investigation
of aminothiol radioprotectors, holds that the
necessary requirements for radioprotectors for
their activity are a two-or three-carbon backbone
separating a thiol or potential thiol and a primary
or secondary amino-functional group, R-NH-C,-
C,-SR’. While this rule is surely an
oversimplification, its precepts have generally
been upheld with few exceptions.
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6.1 Carbon Chain
Certain hydroxylated compounds, especially
those carrying a hydroxyl group at the 2 position,
were active when the amino group carried an
alkyl chain. 3-Amino-propyl phosphorothioates
followed this generalisation, with 2-hydroxy-3-
alkyl aminopropyl phosphorothioates showing some
activity2’.
Functionalisation of either R, or R, in the
series H,NC(R,R,)CH,SH  dramatically altered the
toxicity and/or radioprotective activity. Incorporation
of thiol functions into these alkyl groups greatly
increased the toxicity of the compounds.
Hydroxylation of these alkyl groups increased
the efficacy of the compound relative to the non-
functionalised compound, the phosphorothioates
of this series were generally highly active with
relatively low toxicity2’.
6.2 Thiol Group
A thiol group or a potential thiol group is
generally necessary for radioprotective activity.
Blocked forms of thiols (eg, thiosulphates,
phosphorothioates, disulphides or other derivatives
were most promising from which free thiols may
be formed metabolically) were active to varying
degrees for their ability to latentiate the thiol
and alter the relative potency of the parent amino-
thiol. The blocked thiols have generally been
considered to be prodrugs, whereas the free thiols
were thought to be the active form at the site
of action. The function of the blocking group
was to alter the pharmacokinetics or the rates of
metabolism and excretion of the drugs2’.
6.3 Amino Group
The M-(n-alkylamino)  ethanethiosulphuric acid
series (RNH CH,  CH,  SSO,H)  affords an interesting
pattern of activity with full activity where R includes
a straight chain of up to three carbon atoms. Introduction
of a phenyl group onto the alkyl aminoethane
thiosulphuric acid (resulting in compounds of the
series C,H,  (CH,)n  NH CH,  CH,  SSO,H resulted
in a higher degree of protection for n = 4 and n = 5.
Incorporation of methoxy group on the phenyl ring
4 1 0
of 4-phenyl-n-butyl  aminoethane thiosulphuric
acid resulted in a higher radioprotective effect.
Perhaps the best known alkylamino functionalisation
is the group of aminoalkylaminoethane thiols
and phosphorothioates RNH(CH,)nNH(CH)mSR’,
represented by the prototypic compound WR-2721.
Varying the length of the carbon chain between
the amino groups produced a peak of activity
at n = 3. In contrast to the thiols, phosphorothioates
in this class could be hydroxylated in the aminoalkyl
amino group without loss of activity. As noted
above, the compounds in which n = 2 and m  =
3 were of comparable activity2’  when R’ = H or
PO,H,.
6.4 WR-2721
In 1959, the US Army initiated a programme
to develop radioprotecting drugs at the Walter Reed
Army Research Institute and tested approximately
4400 compounds until 1973. WR-272 1 or amifostine,
ie, S-2 (3-aminopropylamino) ethyl phosphorothioic
acid. The SPO,H  group upon hydrolysis gets converted
into -SH group. It has been found to be accepted
globally after undergoing preclinical and clinical
studies. It is used in cancer patients to reduce the
toxicity of radiotherapy and chemotherapy (systemic
toxicity). The phosphorylated aminothiols presented
a major improvement over the earlier compounds
wrt activity, tolerance, and duration of action, but
still had undesirable side effects such as nausea,
vomiting, and hypotension. It has been used successfully
in protecting bone marrowz,  head and neck radiotherapy
combined with chemotherapy23,  in protecting
gastrointestinal tract24, etc. A critical consideration
in the implementation of protective strategies is
that the tumor must not be protected. There has not
been any evidence of tumor protection in clinical
trials with WR-2721 in short and medium term
follow up studies.
A large number of studies have been carried
out by Yuhas25-27 on WR-2721 in understanding
different pharmacological and toxicity aspects in
radioprotection. Different biological factors which
affect radioprotective efficacy and how differential
chemoprotection is offered by WR-2721 to the normal
and malignant tissues, have been elaborated.
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6.5 Vitamins as Radioprotectors
In recent years, there has been an increasing
interest in the effect of micronutrients (ie, vitamin E,
vitamin C, retinoic acid, selenium, and zinc) on
cancer2*  based on the theory that free radicals play
a role in carcinogenesis29.  Vitamin E (a-tocopherol)
is known as a micromembrane stabilisePO.  It protects
against cell membrane damage from lipid peroxidation
by scavenging free radicals3’.  Clinical use of vitamin E
has been found to be safe even at an oral dose32
as high as 3200 mg/day. Vitamin C and vitamin E
along with butylated hydroxytoluene have been
demonstrated to be effective in not only inducing
glutathione S-transferase activity, but also protecting
against chemical carcinogenesis in rats33.
More recently, tocopherol monoglucoside (a-TMG)
has been found to afford protection against radiation
damage when administered after irradiation. Protection
against lethal irradiation doses as well as against
sublethal irradiation doses has been reported. A
variable DMF value was however observed for the
protection of bone marrow cells from radiation-
induced cytogenetic damage, viz., chromosome
aberrations and micronuclei34.  Interestingly, in tumor-
bearing mice, administration of TMG does not
appear to protect tumor cells against radiation-
induced DNA damage, while protecting the normal
cells35.  Protection afforded by TMG when administered
post-irradiation suggests its possible utility for
protection against accidental radiation exposures.
6.6 Bisbenzimidazole-based DNA Ligands
The clear role of DNA as the critical molecular
target of radiation action has prompted the development
of radioprotective agents that directly interact with
DNA. The DNA ligands, bisbenzimidazole
Hoechst-33258 (H-258) and its analogue Hoechst-
33342 (H-342), which binds selectively in AT-rich
regions of the DNA, minor groove have been shown
to protect DNA against radiation damage in aqueous
solutions and cells. Studies with plasmid  DNA on
strand break formation and DNA sequencing gel
analysis have indicated the reduction in overall
level of strand breaks as well as pronounced inhibition
of breakage in regions that coincide with known
binding sites of the ligand36.
The mechanisms of radiomodification by Hoechst
compounds are not yet clear, although their ability
to scavenge OH radicals as well as quench DNA
radicals has been demonstrated in aqueous solution37.
Recently it has been shown that non-toxic doses
of both H-342 and H-258 can provide significant
protection against wholebody irradiation in mice3*.
Considerable reduction of cytogenetic damage in
the bone marrow cells and longer animal survival
have been observed. Intravenously administered
H-342 binds largely to the nuclear DNA in euoxic
cells but less to the hypoxic tumor cells, and therefore,
may not protect hypoxic tumor cells to a significant
extent39.  Therefore, the radiosensitising effects of
H-342 have also been investigated in human and
murine tumor cells in vitro as well as in vivo.
Available evidences show that addition of H-
342 one hour before irradiation can protect cells
[human glioma brain malignant glioma (BMG -1)
and ehrlich ascites  tumor (EAT)] against DNA and
cytogenetic damage as well as cell death. Addition
of H-342 immediately following irradiation sensitises
cells40.
In the ehrlich ascites  tumor-bearing mice,
intravenous administration of H-342 one hour before
focal irradiation of the tumor enhanced radiation-
induced growth delay in a dose-dependent manner
and resulted in complete regression of the tumor
in more than 50 per cent of the animals at a dose
of 10 mg/kg  body weight. At this dose, a cure rate
(tumor-free survival for more than 100 days) of
55 .per  cent was observed. Taken together, these
results clearly indicate that the DNA ligand H-342
can be a useful radiomodifier in tumor radiotherapy
as it can protect the normal cells while sensitising
the tumor cells4’.
Recently, two more analogues of Hoechst-33258,
namely 5-(4-methylpiperazin-l-yl)-2-[2’-3,4
dimethoxyphenyl)-5’-benzimidazolyl]  benzimidazole
(DMA) and 5-(4 -methylpiperazin- 1 -yl)-2-[2’{  2”(4-
hydroxy-3 methoxyphenyl)-5”-benzimidazolyl)-5’-
benzimidazolyl] benzimidazole (TBZ) have been
synthesised, which demonstrate radioprotective effects
similar to the parental in vitro compound, but with
minimum toxicity42.
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6.7 Non-protein Sulphydryl Release
One of the effects of at least some exogenously
administered thiol or disulphide radioprotectors is
to displace endogenous radioprotectant compounds
that are contained in natural nonprotective mixed
sulphide forms within the cell.
This non-protein sulphydryl (NPSH) release
hypothesis4346 suggests that radioprotection results
from the released endogenous sulphydryl compounds
(mainly glutathione), which function, in turn, to
prevent radiation damage by radical scavenging
and hydrogen donation. This hypothesis is based
on the observation that the ability of sulphydryl
compounds to increase cellular levels of NPSH
correlates well with their radioprotective effectiveness*
47
Glutathione may exert protective activity in
ways that may not be mimicked by other thiol-
containing radioprotectors4’.  However, recent research
on the nature of those thiols present in naturally
occurring protein-thiol mixed disulphides tends not
to support the theory, because only a small fraction
of the low molecular weight thiols bound to protein
have been identified as glutathione.
Diltiazem is a benzothiazepine and calcium
antagonist used in the treatment of cardiovascular
diseases. It has been observed to protect against
bone marrow damage and mortality in wholebody
irradiated mice (10 Gy).
Endogenous colony formation unit (CFU) counts
in spleen of mice administered 110 mg/kg body
weight of diltiazem before 10 Gy wholebody irradiation
have been found to be 6-times more than in the
irradiated animals. Pretreatment with diltiazem abolishes
radiation-induced lifespan shortening and post-
irradiation (10 Gy) administration of diltiazem
marginally (- 15 %)  enhances the survival.
Although the mechanism involved in the
radioprotection by diltiazem is unknown, possible
free radical scavenging, prevention of calcium
influx, and reduction of ATP levels resulting in
reduced enzyme-mediated cell death, have been
proposed’7*48,49.
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7. RADIOPROTECTION BY COMBINED
AGENT REGIMENS
The basic reason for combination of radioprotectors
is to obtain a reduced toxicity with greater protective
efficacy and therapeutic potential. By using a single
radioprotector, this is most often not achievable.
Search for more active and less toxic than MEA,
AET, 5-HT,  or WR-2721 against acute radiation-
induced death in mammals has necessitated the use
of most active mixtures of chemical protectors.
The most effective radioprotective agents exhibit
toxicities that can limit their usefulness. It may be
possible to use a combination of agents with different
radioprotective mechanisms of action at less toxic
doses, or to reduce the toxicity of the major protective
compounds by adding another reagent. The known
mechanisms of action of potential radioprotective
agents and varying effects of different doses and
times of administration in relation to radiation exposure
must be considered when using combined agent
regimens. The combined radioprotector regimen
namely 5-HTP  + AET has been investigated extensively.
7.1 Combination of 5-HTP & AET
.The combination of 5-HTP and AET (5:l by
weight ratio) has been proved to be much better
for radioprotective purposes than 5-HTP  alone against
a lethal ‘y-ray dose of 10.5 Gy and 12.5 Gy, without
any significant toxicity to any other tissue or organ
except kidney and testis. Further, it has been observed
that kidney damage in 50 per cent of the animals
and testis damage in all animals are completely
reversed at some stage I6  A complex is formed between.
5-HTP  and AET and radiation-induced changes in
the complex have also been notedso.
7.2 Combination of 5-HTP & MPG
A combination of 5-HTP  and MPG protects the
wholebody of mice up to a dose of 10.5 Gy, but
the effect was significantly reduced at 12.5 Gy.
Similarly, a combination of 5-HTP  + cysteamine
has been found to provide protection against 10.5 Gy,
which is marginally higher than 5-HTP  a10ne16.  In
all these studies with the combinations, the thiol
drugs (eg, MPG, MEA, etc) were ineffective in
rendering protection after wholebody y-irradiation.
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7.2.1 Mechanism OfRadioprotection  by 5-HTP+AET
in Different Biological Systems
It has been found that 5-HTP  + AET in the
weight ratio of 5:l (ie, 100 mg; 20 mg) provides
protection to mice jejunum5’,  bloods*,  and urines3,
kidney, sperm cellss4, sialic acids in testis and
plasma cells55,  bone marrows6,  splenic cellss7,  etc
in the range 4 Gy to 12 Gy. Normalcy appeared
in these different cells at different time intervals
after different doses of irradiation. The working
hypothesis proposed is that since S-HTP or AET
alone does not provide protection against lethal
dose, the possibility of formation of a complex
between 5-HTP  and the thiol drug cannot be ruled
out. It might be that the thiol drugs help S-HTP
at the receptor sites by some unknown mechanism
and enhance the radioprotective action of 5-HTP.
The different radiolytic products that are formed
from  5-hydroxy-L-tryptophan  and 5-hydroxy  tryptamine
have been indicateds8.  Binding of 5-HTP  with AET
is in the form of a secondary amide. The complex
is stable for 6 days at room temperature. With
y-radiation, there is a consistent decrease in pH
for 5-HTP  and AET, but for 5-HTP  + AET combination
the change in pH is biphasic34.  The changes that
occur in 5-HTP  upon y-irradiation are deamination
from the side chain, decarboxylation from the side
chain, intermolecular hydrogen bonding through
5-hydroxyl  group, which gets deformed upon irradiation,
and cleavage of the double bond in the p carbon
atom in 5-HTP  takes place upon irradiation5g*60.
The AET gets converted to MEG and this
conversion is facilitated in alkaline PH.  Auxochromes
like
SH,-S-C=NH,  NH,’ a n d  H&-C=NH
I
NH2
are responsible for increased absorption and
fluorescence with increase in alkalinity. IR studies
indicate that C-S-C linkage of AET gets distorted
as a result of y-irradiation6’.  Perturbation and stretching
of =NH, -NH,  and H,N-C=NH takes place as a
result of y-irradiation. Protection mechanism of
AET is by its conversion to MEG and scavenging
of OH”  radicals up to 2.5 Gy as evidenced by
analytical techniques61*62. 5-HTP  + AET complex
does bind to DNA of different types of cells mentioned
earlier where they contained DNA. Binding the
complex provides protection by not allowing the
free radicals to interact with DNA directly.
The molecular weights of 5-HTP  and AET are
low and even after complex formation, when it is
incorporated intraperitoneally, it is possible that
either the complex binds to the cell membrane and
alters its functional aspect, or it penetrates the cell
membrane and interacts with cytoplasmic and nuclear
structures.
A combination of 5-HTP+  AET (5: 1 by weight
ratio) has proved to be much better for radioprotective
purposes than 5-HTP  alone against lethal doses of
10.5 Gy and 12.5 Gy of y-irradiation. Daily
administration for 15 days in normal, double, triple,
and quadruple the radioprotective dose of 5-HTP
+ AET formulation in Wistar rat has caused no
damage to any tissue or organ except kidney and
testis. Routine hematological examination and
biochemical estimations of blood and urine have
yielded normal values. Reversal studies done after
30 days of stopping the drug administration have
shown that in 50 per cent animals kidney histological
damage disappeared and in all the animals, testis
damage was completely cured. No neurotoxic symptom
was noted at any stage63.  5-HTP  + AET was encapsulated
in RBC membrane ghost and it was found to provide
radioprotection against lethal dose at about 1/200th
amount needed for radioprotection compared to
free 5-HTP  + AET. It has been found to protect
different organs against radiation damage64*65.  It
has been suggested that the combination can be
made more versatile by mixing vitamin C, vitamin E,
and salts66  of manganese (Mn) and zinc (Zn).
Most of the active sulphur-containing
radioprotective chemicals are toxic to living systems.
The combined regimen of sulphur-containing
radioprotectors decrease DNA synthesis and prolong
the cell cycle of stem cells in small intestine. But
in protective dose, nucleus, mitochondria, and
endoplasmic reticulum get structurally deformed6’.
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It has been found that polysaccharides alone
render radioprotection against 6.5 Gy x-rays. The
four polysaccharides extracted from yeast
Saccharomyces cerevisiea or from yeast Rhodotorula
rubra displayed a significant radioprotection with
a dose-reduction factor close to 2. The protection
is offered to the bone marrow. The erythropoetic
system does not appear to be involved in the protective
actiond8.
Organic zinc salts (eg, zinc aspartate, zinc histidine,
zinc orotate, and zinc acetate) reduce the fall of
heamatocrit, thrombocytes, erythrocytes, and leukocytes
in irradiated mice. Zinc-aspartate affords synergistic
heamatological protection and does not enhance
the toxicity of WR-272 1. Probably, zinc aspartate
stabilises exogenous and endogenous thiols by forming
zinc-thiol complexes69.
WR-2721 when mixed with MPG in the ratio
of 50  mg/kg:  20 mg/kg  protects bone marrow
cells against radiation dose as determined by
chromosomal aberration studies with increase in
dose of drug administered protection increased.
Administration of MPG after WR-2721 helps to
maintain the higher GSH level compared to WR-272 1
alone’O.
After sublethal dose of irradiation, WR-272 1
is considered the best for radioprotecting normal
tissues as DRF = 4.5 for mouse bone marrow
chromosome as biological end-points. MPG showed
a DRF = 2.6 for the same dose and biological
end-point. By combining these two drugs, it is
possible to minimise toxic effect and increase
protective effect ‘I. Toxicity of WR-2721 could
be reduced using Ocimum sanctum. This particular
combined regimen significantly enhanced bone
marrow radioprotection against radiation dose.
This indicates that flavanoid compounds present
in Ocimum sanctum are capable of giving increased
radioprotection72.
Biological-response modifiers like glucan are
potential therapeutic agents as these stimulate immune
system to fight cancer. Glucan has a DRF of 1.2
to 1.3, but when it is mixed with WR-2721, the
DRF increases to 1.5-l .6.  Glucan appears to reduce
the behavioural toxicity of WR-272173.
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These are some of the examples that indicate
the efficacy of combined agents as a promising
approach for maximising radioprotection with minimal
toxicity.
8. RADIOPROTECTION
8.1 Behavioural Radioprotectors
Under many circumstances, exposure to ionising
radiation can impede performance significantly. After
large doses, lethal or supralethal, behavioural effects
are rapid (within minutes) but up to 10 Gy, performance
deficits develop rather slowly and are long-lasting.
All tasks are not radiosensitive equally, tasks with
complex and demanding requirements may be disrupted
even at low radiation doses (C  1 Gy). Combined
injuries can act synergistically with radiation exposure
to greatly increase behavioural deficits. Most of
the radioprotectors  developed todate  are themselves
behaviourally toxic at radioprotective as well as
non-radioprotective doses, and the adverse effects
are further aggravated in the presence of radiation.
A very limited number of radioprotectors have been
found to give behavioural radioprotection at very
low, almost non-toxic doses75.
With accidental radiation dose, supralethal
doses produced early transient incapacitation and
early performance decrement, invariably followed
by confusion, irritability, restlessness, coma, and
death. Lower radiation doses may produce mild
but persistant behavioural changes characterised
by weakness  and fatigue76.  The different
radioprotectors that have been tried on rats to
observe conditioned taste aversion for a dose up
to 1 Gy are diltiazem, ondansetron, Hoechst,
and ginseng at dose levels of 5 mg/kg,  2 mg/kg,
2 mg/kg,  and 50 mg/kg  body weight. Relative
saccharin consumption has come to closest value
of unirradiated control for ginseng. WR-2721,
an excellent radioprotectant, has been extensively
evaluated for its side effects and has been found
to be behaviourally toxic. In all the species tested
(eg, mice, rats, and monkeys), it disrupted behaviour
and performance when administered alone, and
in the presence of radiation, degradation was
further aggravated“. The compounds that have
been tried are metoclopramide, dazopride, and
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zacopride for monkeys after exposure to 8 Gy
y-radiation. These drugs are effective anti-emetics’*.
8.1.1 Practical Application of Behavioural
Radioprotectors
For the space explorers beyond earth’s protective
atmosphere, emesis will be a problem due to space
radiation and motion sickness, ie, space adaptation
syndrome. A study in monkeys to test for synergy
between radiation and motion reported that the
emesis ED,, was 4.5 Gy for radiation alone, and
2.6 Gy for radiation plus motion79.  Mechanisms of
emesis produced by radiation and motion are different,
so combined drug regimens are neededso.
The important point here is that performance
requirements can change traditional toxicity end-
points, and thus, determination of behavioural toxicity
combined with lethality may be more meaningful
than looking at lethality alone. Finally, since these
end-points differ in terms of effect levels, it may
be the reason that finding behavioural radioprotectors
has not been easy and /or that the behavioural
findings reported may be negative.
8.1.2 Clinical Implications of Behavioural
Radiopro tection
Recently, there has been considerable interest
in the use of implanted radionuclide sources for
the treatment of brain neoplasms, but focal irradiation
injury poses the most serious problem. It has been
also observed that during cranial radiation therapy,
there is substantial risk of intellectual deterioration
in patients, leading to significant alterations in
their quality of lifes’.
8.2 Herbal Radioprotectors
The rationale for using herbal preparations as
radioprotectors is that these have proved to be
non-toxic to human beings and are already being
used for different types of ailments, readily available,
inexpensive, and works upon digestive system and
heamatopoetic system82-84.
Oral administration of Liv-52 has been shown
to protect mice against wholebody irradiation at
moderate doses (- 3 Gy). Radioprotective activity
has been attributed to the inhibition of lipid peroxidation
by increasing the level of a-tocopherol and glutathione
reduction in the cytogenetic damage8S*86.
Both orientin  and vicenin obtained from the
extract of Ocimum sanctum protect against death
from gastrointestinal syndrome as well as from
bone marrow syndrome when injected intraperitonially
before wholebody exposure to lethal y-radiation
(11 Gy). Though optimum dose for radioprotection
was found to be 50 pg/kg  body weight, 100 pglkg
body weight dose also did not have any acute
toxicity. The protection by vicenin with DRF 1.37
was slightly better than orientins  with DRF 1.30.
The protection has been ascribed to the antioxidant
property to inhibit lipid peroxidation and free radical
scavenging property of these compoundss3.
8.2.1 Mentha  Piperita
A dose of 1 g/kg body weight per day when
administered before a y-radiation dose of 8 Gy was
found to protect Swiss Albino mice. The DRF value
was found to be 1.78 with a biological end-point
,of,  different types of chromosomal damage (eg,
dicentrics, sister chromatid exchange, acentric
fragments, etc). A combination of antioxidative
and antimutagenic activities via modulation of DNA
repair processes may be held responsible for the
radioprotective effect of Mentha  piperita8’.
8.2.2 Ginkgo Biloba
Extract (Eglo 76 1) containing flavonoids and
terpenoids at a dose of 3 x 40 mg/person  for t w o
months gave protection to persons of Chernobyl
accident. The radiation exposure varied from 1 cGy
to 1.95 Gy. The biological end-points were different
types of chromosomal aberration (eg, ring formation,
dicentrics, telomeric expulsions, chromatid breaks,
etc.). Anticlastogenic effect was observed in the
plasma of the persons irradiated. This anticlastogenic
effect is due to oxidative stress. So, it can be
influenced by antioxidant in vivo. Prophylactic use
of antioxidants can be discontinuous, thus reducing
the cost of intervention trialss8.  Superoxide anion,
which is directly or indirectly implicated in cell
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damage, is scavenged by Ginkgo biloba extract. Its
antiradical effect was demonstrated by low-temperature
electron spin resonance and in a non-enzymatic
system by polarographic determinationjg.
Mammary tumorigenesis was induced in female
rats with a dose of @‘Co-y  rays for a wholebody
irradiation of 1.5 Gy. From a tumor induction value
of 70.3 per cent, there was a reduction of 18.5 per
cent of tumor incidence when the rats were fed
curcumin  during initiation stage. Appearance of
first palpable tumor was delayed by 6 months in
the curcumin-fed group. By histological examination,
the protection of adenocarcinoma (16.7 %) in total
tumors in the curcumin-fed rats was found to be
decreased to half that in (32.1 %)  in the control
group. At the time of irradiation, curcumin  did not
have any effect on organ weight or on the development
and differentiation of mammary glands of pregnant
rats. The serum concentration of fatty acids,
thiobarbituric acid-reactive substances, and ovation
and pituitary hormones, except LH, remained at
the control level. The results suggest that curcumin
does not have side effects and is an effective agent
for chemoprevention acting at the radiation-induced
initiation stage of mammary tumorigenesisgO.
The results seem to be promising from mice
model studies. There is a scope to further explore
the potentiality of these herbal drugs for higher
species. In some of these extracts, the active principle
of the working of these herbal extracts has been
explained. As these extracts contain a large number
of ingredients, the mode of action is complex. The
mechanism of radioprotection might be antioxidant,
radical scavenging, and immunomodulation.
Accessibility of different organs by oral route, relatively
easier excretion of unwanted compounds after absorption
of active and effective components are some of the
promising points for these herbal drugs. But to put
these herbal drugs as radioprotectors, one needs to
know the following:
(a) The exact composition
(b) Mechanism of action of each component
(c) Possibility of synergistic action between different
components
4 1 6
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Exploration regarding mechanism of action as
radioprotectors
Elimination of the toxic components from the
extract
Pharmacokinetics of the different components
in the body organs
Some physico-chemical parameters like membrane
permeability, interaction possibilities with cellular
and nucleolar membranes, diffusion coefficient
of the components, interaction possibilities with
body fluids, biodistribution etc.
8.3 Prospective Aspects of Radioprotectors
Unfortunately, none of the radioprotectors available
today ideally meets all the requirements of a
radioprotector mentioned before. The limitations
of chemical radioprotectors are:
(a) These have to be administered before irradiation.
(b) Their toxicity cannot be totally eliminated.
(c) These are not always suitable for oral administration.
(d) The metabolic products take long time for excretion.
Although combining more than one radioprotector
with different mechanisms of action would be one
of the approaches, attempts to use such combinations
in bigger animals have met with limited success
either due to poor protection or higher toxicity.
However, design and identification of new chemicals
with low systemic toxicity and DRF values of 1.5
or more still holds promise for the futuregl.  Further,
the toxicity can be brought down substantially by
encapsulating the radioprotectors (singly or in
combination) in erythrocyte membrane ghosts,
liposomes, nanoparticle, or polystyrene microspheres.
Thus, these can be targeted more easily to the
organs of interest and also eliminate the requirement
of large doses without compromising the efficacy.
Alternatively, the use of complex natural products
(herbal preparations) from plants, fru’its, leaves,
etc, has received much attention in the last decade
and appears to be favourable in many respects as
compared to chemical radioprotectors84*g2-g4.  These
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include lower toxicity in human beings (as many
of these are used in alternative medicine in Asian
countries for centuries), are easily available and
inexpensive, and have shown good radioprotection
in preclinical studies.
Further, accessibility to different organs following
oral administration, relatively easier excretion of
undesirable toxic components after absorption of
active and effective components, are some of the
other promising aspects. Elucidation of the mechanisms
of action, partial purification (fractionation) to reduce
toxicity without compromising efficacy, information
on pharmaco-kinetics, and bioavailability for many
of the currently investigated complex natural products,
should make these an attractive class of radioprotectors
in the future. Identification of two flavonoids, orientin
and vicenin as active components of Ocimum sanctum
has been donea*84*95.  Elucidation of their mechanisms
of action is an important advancement in this direction.
Further, combining some of the chemical radioprotectors
with herbal extracts, as has been shown in the case
of WR-2721 and Ocimum sanctum72,  is also an
attractive approach.
Diseased sites in all the organs namely brain96*97,
easophagus98,  lungs99,  breastlOO*‘O’,  kidneylo2,  cervixlo
are accessible to different types of chemotherapeutic
agents. It is possible that the onset of carcinogenesis
or tumor genesis due to ionising radiation exposure
can be regressed by suitable choice of chemical
radioprotectors with proper combination of
radiotherapy. It has been recently observed that
radioprotectors present in herbal extracts show minimum
toxicity and are tolerated to the maximum extent.
If the active principles of their radioprotective
efficacy could be worked out, these may prove to
be of utmost use. Alternatively, if the synthetically
prepared radioprotectors are so designed that these
will give minimum toxicity and maximum
radioprotective efficacy, these may also be developed
further.
REFERENCES
1. Capizzi, R. Amifostine, the preclinical basis
for broad spectrum selective cytoprotection of
normal tissues from cytotoxic therapies. Seminars
in Oncology, 1996, 23 (suppl 8). 2-17.
2 .
3 .
4 .
5 .
6 .
7 .
8 .
9 .
Uma Devi, P. Normal tissue protection in cancer
therapy: Progress and prospects. Acta  Oncology,
1998, 37(3),  247-52.
Weiss, J.F. & Landauer, M.R. Radioprotection
by antioxidants. Annals of the New York Acad.
Sci., 2000, 899, 44-60.
Wasserman, T. Radioprotective effects of
amifostine. Seminars in Oncology, 1999,26(2),
(suppl 7). pp. 89-94.
Weiss, J.F. & Landeur, M.R. Protection against
ionising radiation by antioxidant nutrients and
phytochemicals. Toxicology, 2003, 189 (l-2),
l-20.
Alper, T. Cellular radiobiology. Cambridge
University Press, London, 1979.
Carr, J.; Huff, J.E.; Fisher, K.D. & Huber, T.E.
Protective agents modifying biological effects
of radiation. Archives Environ. Health, 1970,
20, 88-98.
Chapman, J.D. & Reuvers, A.P. The time scale
of radioprotection in mammalian cells. Experentia.
1977, 27(suppl),  9-18.
Edwards, J.C.; Chapman, D.; Cramp, W.A. &
Yatvin, M.V. The effects of ionising radiation
on biomembrane structure and function. Prog.
Biophys. Mol. Biol., 1984, 43, 7 l-93.
10. Ferle Vidovic, A.; Petrovic, D.; Vidic, Z.; Osmak,
M. & Kadizak, K. Absence of 2-aminoethyl
isothiouronium bromide hydrobromide protection
against fast neutrons: Cellular effects. Radiat.
Environ. Biophys., 1981, 19, 197-04.
11 Singh, A. & Singh, H. Time scale and nature
of radiation-biological damage: Approaches to
radiation protection and post-irradiation therapy.
Prog. Biophys. Mol. Biol., 1982, 39, 69-107.
12. Dwarakanath, B.S.; Adhikari, J.S. & Jain, V.
Hematoporphyrin derivatives potentiate the
radiosensitising effects of 2-DG  in cancer
cells. Int. J. Radiat. Oncol. Biol. Phys., 1998,
43, 1125-133.
417
DEF SC1  J, VOL. 55, NO. 4, OCTOBER 2005
13. Dwarakanath, B.S.; Koshi, L.; Raj, H. J.; Parmar,
V.S. & Mathew, T.L. Acetylated phelyphenols
as radiomodifiers. In International Conference
on Biodiversity and Natural Products: Chemistry
and Medical Applications, 26-3 1,2004.  Delhi.
India.
14. Freeman, B.A. & Crapo, J.D. Biology of disease:
Free radical and tissue injury. Laboratory
Investigations, 1982, 47, 412-26.
15. Puck, T.T. & Marcus, PI. Action of x-rays
on mammalian cells. J. Exp. Med., 1956, 103,
653-66.
16. Ghose, A.; Ganguly, S.K. & Joginder Kaur.
Protection with combination of hydroxytryptophan
and some thiol compounds against wholebody
gamma radiation. Int. J. Radiat. Biol., 1983,
44, 175-81.
17. Goel, H.C.; Ganguly, SK.; Prasad, J. & Jain,
V Radioprotective effect of diltiazem on cytogenetic
damage and survival in gamma ray-exposed
mice. Ind. J. Exp. Biol., 1996, 34, 1194-2000.
18. Upadhyay, S.N.; Singh. S.; Bhardwaj, R.;
Chaudhury, N.K. & Lazar Mathew,  T .  A
preliminary study on 5-hydroxy-L-tryptophan,
L-cysteine and cystamine. J. Ind. Chem. Sot.,
2003, 80, 33-35.
19. Giambarresi, L. &Jacobs, A.J. Radioprotectants.
In Military radiobiology, edited by J.J. Conklin
and Richard. I. Walker. Academic Press Inc,
New York, 1987. pp. 275-76.
20. Till, J.E. & MC Culloch, E.A. Direct measurement
of the radiation sensitivity of normal mouse
bone marrow cells. Radiation Research, 1961,
14, 213-22.
2 1 Livesey, J.C.; Reed, D. J. & Adamson,  L.F. 2 1.
Livesey, J.C.; Reed, D.J. & Adamson,  L.F. Radiation
protective drugs and their reaction mechanisms.
Noyes  Publications, Park Ridge, New Jersey,
USA, 1985. pp.105-08.
22. Coia, L.; Krigel, R.; Hanks, G.; Comis, R.; 3 1. MC Cay, P.B. Vitamin E: Interactions with free
Algazy, K.; Peters R.; MC Culloch, W. & Sehein, radicals and ascorbate. Ann. Rev. Nature, 1985,
P. A phase I study of WR 2721 in combination 5, 323-40.
with total body irradiation in patients with refractory
lymphoid malignancies. Int. J.  Radiat. Oncol.
Biol. Phys., 1992, 22, 791-94.
23. MC Donald, S.; Meyerowitz, C.; Smutzin, T.B.S.
& Rubin,  P. Preliminary results of a pilot study
using WR 2721 before fractionated irradiation
of the head and neck to reduce salivary gland
dysfunction. Int. J. Radiat. Oncol. Biol. Phys.,
1994, 29(4),  747-54.
24. Liu, T.; Liu, Y.; He, S.; Zhang, Z. & Kliggerman,
M.W. Use of radiation with or without
WR 2721 in advanced rectal cancer. Cancer,
1992, 69, 2820-825.
25. Yuhas, J.M.; Proctor, J.O.; & Smith, L.H.
Some pharmacologic effects of WR-2721: Their
role in toxicity and radioprotection. Radiation
Research, 1973, 54, 222-33.
26. Yuhas, J.M. Biological factors affecting the
radioprotective efficiency of S-2-(3-
aminopropylamino) ethylphosphorothioic acid (WR-
2721): LD,, (30) doses. Radiation Research, 1970,
44, 621-28.
27. Yuhas, J.M. & Storer, J.B. Differential
chemoprotection of normal and malignant
tissues. J.  Nat. Cancer Inst.(JNCI), 1969, 42,
331-35.
28. Borek, C. Nutritional, hormonal and enzymatic
factors as modulators of radiation and chemical
oncogenesis in vitro. In Radioprotectors and
anticarcinogens, edited by O.F. Nygaard and
M.G. Simic.  Academic Press, New York, 1983.
pp. 495-13.
29.
30.
Oberley, L.W. Modulation of cancer by
superoxide dismutase: Oncology overview.
Pub. Znt. Cancer Res. Databank (ICRDB),
NCI, 1976.
Lucy, J.A. & Dingle, J.T. Fat-soluble vitamins
and biological membrane. Nature, 1964, 204,
156-60.
4 1 8
UPADHYAY, et al.: CHEMICAL RADIOPROTECTORS
32, Bendicai, A. & Macailin, L.J. Safety of oral
intake of vitamin E. Amer. J.  clin.  Nutri., 1988,
48, 612-19.
33. Chen, L.H. & Shiau C.A. Induction of glutathione
S-transferase activity by antioxidants in hepatocyte
culture. Anticancer Research, 1989, 9, 1069-
072.
34. Satyamitra, M.; Uma Devi, P.; Murase, H. 8z
Kagiya, V.T. In vivo post-irradiation protection
by a vitamin analogue, alpha-TMG. M.G. Radiation
Research, 2003, 160 (6), 655-61.
3 5. Nair, C.K.K.; Salvi, V.; Kagiya VT.; & Rajagopalan,
R. Relevance of radioprotectors in radiotherapy:
Studies with tocopherol monoglucoside. J. Env.
Pathol. Toxicology Oncol., 2004, 23, 153-60.
36. Denison, L.; Haigh, A.; D#  Cunha, G. & Martin,
R.F. DNA ligands as radioprotectors: Molecular
studies with Hoechst 33342 and Hoechst 33258.
Znt.  J. Radiat. Biol., 1992, 61(l),  69-81.
37. Adhikari, J.S.; Dwarakanath, B.S.; Khaitan,
D.; Chandna, S.; Manickam, J.; Lazar, Mathew,
T. & Jain, V. Heterogeneity in the radiobiological
effects of DNA ligand Hoechst-33342 in human
tumor cell lines. In Radiobiology: International
Conference on Radiation Biology, 17-  19 February
2000, Trivanndrum, India, 2000.
38. Singh. S.P.; Jayanth, V.R.; Chandna, S.;
Dwarakanath, B.S.; Singh, S.; Adhikari,
J.S. & Jain, V. Radioprotective effects of
DNA ligands Hoechst-33342 and Hoechst-33258
in wholebody-irradiated mice. Znd. J. Exp. Biol.,
1998, 36, 375-84.
39. Chaplin, D.J.; Durand, R.E. & Olive, P.L. Cell
selection from a murine tumor using the fluorescent
probe Hoechst-33342. Brit. J. Cancer, 1985,
51, 569-75.
40. Dwarakanath, B.S.; Kapoor, N.; Chandna, S.;
Adhikari, J.S.; Singh, S. & Jain, V Radiomodifying
effects of DNA ligand Hoechst in transformed
mammalian cells. In Trends in radiation and
cancer biology, edited by R.N. Sharma. Bilateral
41.
42.
43.
44.
45.
4 6
Seminars of the International Bureau, Julich,
1998, 29, 81-89.
Dwarakanath, B.S.; Singh, S. & Jain, V.
Optimisation of tumor radiotherapy, Part V:
Radiosensitisation by 2-deoxy-D-glucose  and
DNA ligand Hoechst-33342 in a murine tumor.
Ind. J. Exp. Biol., 1999, 37, 865-70.
Tawar, U.; Jain, K.A.; Dwarakanath, B.S.;
Chandra, R.; Singh, Y.; Chaudhury, N.K.;
Khaitan, D. & Tandon,  V. Influence of phenyl
ring disubstitution on bisbenzimidazole and
terbenzimidazole cytotoxicity: synthesis and
biological evaluation as radioprotectors. J.
Med. Chem., 2003, 46, 3785-3792.
Klayman, D.L. & Copeland  E.S. Radioprotective
agents. In Kirk Othmer Encyclopedia of
Chemical Technology Ed. 3, Vol. 9, edited
by M. Grayson  & D. Eckroth. Wiley, New
York, 1982. pp. 801-32.
Copeland, E.S. Mechanisms of radioprotection.
A review. Photochemistry Photobiology, 1978,
28, 839-44.
Revesz, L. & Modig, H. Cystamine-induced
increase of cellular glutathione level: A new
hypothesis of the radioprotective mechanism.
Nature (London), 1965, 207, 430-31.
Modig, H.G. & Revesz, L. Non-protein sulphydryl
and glutathione content of ehrlich ascites tumor
cells after treatment with the radioprotectors
AET, cysteamine, and glutathione. Znt. J. Radiat.
Biol., 1967, 13, 469-77.
47,  Revesz, L; Edgren, M.; & Nishidai, T. Mechanisms
of inherent radioprotection in mammalian cells.
In Modification of radiosensitivity in cancer
treatment, edited by T. Sugahara. Academic
Press, New York, 1984. pp. 13-29.
48. Floesheim, G.L. Radioprotective effects of calcium
antagonists used alone or with other types of
radioprotectors. Radiation Research, 1993,133,
80-87.
419
DEF SC1  J, VOL. 55, NO. 4, OCTOBER 2005
49. Upadhyay, S.N. A study on the physico-chemical
characteristics of radioprotector dilitiazem and
its binding with deoxyribonucleic acid and its
constituent bases. J. Surface Sci. Technol., 200 1,
17(3-4),  157-67.
50. Upadhyay, S.N.; Singh, S. & Ghose, A. Physico-
chemical properties of a combination of
5-hydoxy-L-tryptophan  w i t h  /3-aminoethyl
isothiouronium bromide hydrobromide. J. Ind.
Chem. Sot.,  1993, 70, 681-87.
5 1. Ghose, A.; Basu, S.K.; Ganguly, S.K.; Bhatnagar,
A. & Mathur, M. Role of some radioprotectors
on sgFe  uptake in bone marrow after
wholebody gamma irradiation to mice.
Strahlentherapie 57, 1983, 59, 772-74.
5 2 Basu, S.K.; Chandra, K. & Chuttani, K.
Radioprotection of peripheral blood cells with
a combination of hydroxytryptophan and thiol
compounds in mice. Acta  Onkologica, 1987,
26, 229-32.
53. Basu, S.K.; Srinivasan, M.N.; Chuttani, K. &
Ghose, A. Urinary deoxycitidine levels in
radioprotected rats. J. Radiat. Res., 1984, 25,
174-82.
54. Srinivasan, M.N. & Basu, S.K. DNA synthesis
in radioprotected rats after wholebody gamma
irradiation. Ind. J. Nuclear Med., 1986, 1,
4 3 - 4 6 .
55. Srinivasan, M.N.; Basu, S.K. & Ghose, A. Effect
of chemical radioprotectors on serum proteins
of rats exposed to gamma irradiation, Ind. J.
Expl.  Biol., 1985, 23, 490-92.
56. Ghose, A.; Basu, S.K.; Bhatnagar, A. & Sarin,
R.C. Effect of some chemical radioprotectors
on 5gFe  uptake in blood in wholebody gamma
irradiated rats. Radiobiologia Radiotherapia,
1987, 28, 507-09.
57. Dey, J.; Dey, T.B.; Ganguly, S.K.; Nagpal,  K.K.
& Ghose, A. Chemical radioprotection to bone
marrow stem cells after wholebody gamma
irradiation to mice. Strahlentherpie und Onkologie,
1988, 164, 681-83.
58. Upadhyay, S.N. Mechanism of radioprotection
by 5-hydroxy-L-tryptophan.  J.  Ind. Chem. Sot.,
2003, 80, 619-21.
59. Upadhyay, S.N.; Warrier, A.V. & Ghose, A.
Effect of gamma irradiation on HT, 5-HT  and
HT + AET in in vitro system. J. Ind. Chem.
Sot.,  1993, 70, 763-67.
60. Upadhyay, S.N.; Singh, R.P. & Ghose, A.
Stability study of 5-hydoxy-L-tryptophan  and
5-hydroxytrptamine.  Ind. J. Nuclear Med.,
1987, 2, 90-91.
61. Upadhyay, S.N. & Guha, S.N. Mechanism of
radioprotection by b-Amino-ethyl isothiouronium
bromide hydrobromide. J. Ind. Chem. Sot.,  200 1,
78, 337-39.
62. Upadhyay, S.N.; Singh, R.P.  & Ghose, A. Interaction
of 5-hydoxy-L-tryptophan with deoxyribonucleic
acid and nucleohistone. J. Surface Sci. & Technol.,
1993, 9, 67-72.
63. Ghose, A. Radioprotection study with some
radioprotectors in dogs and monkeys (Personal
Communication).
64. Upadhyay, S.N.; Dey, T.B. & Ghose, A.
Radioprotective efficacy of HT + AET in
encapsulated form. Ind J.  Exp. Biol., 1996, 34,
403-07.
65. Upadhyay, S.N.; Sharma, A.; Nagpal, K.K. &
Saini, S.K. Effects of gamma irradiation on the
concentration of 5-hydoxy-L-tryptophan  and 5-
hydroxytryptamine in presence of radioprotector
in Sprague Dawley rats. Def Sci. J., 1997,
47(4),  383-88.
66. Upadhyay, S.N. Search for a better radioprotective
combined regimen. Ind. Photobiology Sot.  (IPS)
Newsletter, 2002, 41, 46-53.
67. Maisin, J.R. Protection against ionising radiation
by combinations of radioprotectors. Pharmacology
Therapeutics, 1988, 39, 189-93.
68. Maisin, J.R.; Kondi, T. & Mattelin, G.
Polysaecharides induce radioprotection of murine
420
UPADHYAY, et al.: CHEMICAL RADIOPROTECTORS
heamopoetic stem cells and increase the LD,,
(30) days. Radiation Research, 1986,105,276-
81.
69. Floresheim, G.L. & Bieri,  A. Further studies
on selective radioprotection by organic Zn salts
and synergism of Zn-aspartate  with WR-272 1.
Brit. J. Radiolo., 1990, 63, 468-75.
70. Uma Devi, P. & Prasamra,  P.G.S. Radioprotective
effect of combinations of WR-2721 and
mercaptoproionylglycine on mouse bone marrow
chromosomes. Radiation Research, 1990,124,
165-170.
7 1. Uma Devi, P. & Thomas, B. Bone marrow cell
protection and modification of drug toxicity
by combination of protectors. Pharmacology
Therapentics,  1988, 39, 213-14.
72. Gnansoundari, A.; Uma Devi, P. & Rao, B.S.S.
Enhancement of bone marrow radioprotection
and reduction of WR-272 1 toxicity by Ocimum
sanctum. Mutation Research, 1998, 397,
303-42.
73. Patchen,  M.L.; Alesandro, M.M.; Chitigos, M.A.
& Weiss, J.F. Radioprotection by biological
response modifiers alone and in combination
with WR-272 1. Pharmacology Therapeutics,
1988, 39, 247-54.
74. Bogo, V. Behavioural radioprotection.
Pharmacology Therapeutics, 1988, 39,
73-78.
75. Mukherjee, S.K. Performance decrement by
exposure to sub-lethal doses of ionising radiations.
Def  Sci. J., 2000, 50(l),  63-74.
76. Wixon, H. N. & Hund, W.A. Ionising radiation
decreases veratridine-stimulated uptake of sodium
in rat brain synaptosomes. Science, 1983, 220,
1073-074.
77. Landauer, M.R.; Davis, H.D.; Dominitz, J.A.
& Weiss, J.F. Dose and time relationships of
the radioprotector WR-2721 on locomotor activity
in mice. Pharmacol. Biochem. Behav., 1987,
27, 573-76.
78. Dubois, A; Fiala, N. & Bogo, V. Treatment of
radiation-induced vomiting and gastric emptying
suppression with zacopride. Gastroenterology,
1987, 92, 1376-380.
79, Conklin, J.J. & Hagon,  M.P. Research issues
for radiation protection for man in prolonged
space flight. In Advances in radiation biology,
Vol. 13, edited by Lett J.T. Academic Press,
New York, 1987. pp. 215-84.
80. Young, R.W. In Mechanisms and treatment of
radiation-induced nausea and vomiting:
Mechanisms and treatment, edited by C.J Davis,
C.J. Lake Bakkar, and G.V. Grahame Smith.
Springer, New York, 1986. pp.94-109.
8 1. Mulhem, R.K.; Ochs,  J. & Kum, L.E. Changes
in intellect associated with cranial radiation
therapy. In Radiation injury to the nervous system,
edited by P.H. Gutin,  S.A. Leibel, and E.G.
Sheline.  Raven Press, New York, 1991. pp. 32540.
82. Sandhir, R. & Gill, K.D. Hepatoprotective effect
of Liv 52 on ethanol induced liver damage in
rats. Ind. J. Exp. Biol., 1999, 37, 762-66.
83. Uma Devi, P.; Ganasoundari, A.; Vrinda, B.;
Srinivasan, K.K. & Unnikrishnan, M.K. Radiation
protection by the ocimum flavonoids orientin
and vicenin: Mechanisms of action. Radiation
Research, 2000, 154, 455-60.
84. Uma Devi, P.; Ganasoundari, A.; Rao, B.S.S.
& Srinivasan, K.K. In vivo radioprotection by
ocimum flavonoids: Survival of mice. Radiation
Research, 1999, 151, 74-78.
85. Ganapathi, N.G. & Jagetia, G.C. Liv 52
pretreatment inhibits the radiation-induced
lipid peroxidation in mouse liver. Current
Science, 1995, 69(7), 601-04.
86. Jagetia, G.C. & Ganapathi, N.G. Inhibition of
clastogenic effect of radiation by Liv 52 in the
bone marrow of mice. Mutation Research. 1989,
224(4),  507-10.
87. Samarth, R.M. & Ashok  Kumar. Menthapiperita
(Linn) leaf extract provides protection against
4 2 1
DEF SC1  J, VOL. 55, NO. 4, OCTOBER 2005
radiation-induced chromosomal damage in marrow
of mice. Ind. J. Exp. Biol., 2003, 41, 229-37.
88. Emerit, I.; Oganesian, N.; Sarkisian, T.; Arutyunyan,
R.; Pogosian, A.; Ashian,  K.; Levy, A. & Cemjavski,
L. Clastogenic factors in the plasma of Chernobyl
accident recovery: Anticlastogenic effect of Ginkgo
biloba extract. Radiation Research, 1995,144,
198-05.
89. Princemail, J.; Dupuis, M.; Nasar, C.; Hans, P.;
Haag Berruier, M.; Anton, R. & Deby, C. Superoxide
anion scavenging effect and superoxide dismutase
activity of Ginkgo biloba extract. Experimentia,
1989, 45(8),  708-12.
90. Inano, H.; Onode,  M.; Inafuku, N.; Kubota,
M.; Kamada, Y.; Osawa, T.; Kobayashi, H. &
Wakabayashi, K. Potent preventive action of
curcumin  .on  radiation-induced initiation of
mammary tumorigenesis in rats. Carcinogenesis,
2000, 21 (lo),  1835-841.
9 1. Maisin, J.R. Chemical radioprotection: Past,
present and future prospects (Bacq  and Alexander
Award Lecture). Int. J.  Radiat. Biol., 1998,
73(4),  443-50.
92. Uma Devi, P.; Rao, B.S.S. & Solomon, F.E.
Effect of plumbagin on the radiation-induced
cytogenetic and cell cycle changes in mouse
Ehrlich Ascites carcinoma in vivo. Ind J. Expl.
Biol., 1998, 36, 891-95.
93. Goel, H.C.; Saji Kumar, S.; & Sharma, A.K.
Effect of podophyllum hexandrum on
radiation-induced delay of post-natal appearance
of reflexes and physiological markers in rats
irradiated in utero. Phytomedicine, 2002,9,447-54.
94. Mittal,  A.; Pathania, V.; Agarwal, P.K.; Prasad,
J.; Singh, S. & Goel, H.C. Influence of podophylhun
hexandrum, an endogenous antioxidant defence
system in mice: Possible role in radioprotection.
Journal of Ethnopharmacology, 200 1,76,253-62.
95. Uma Devi, P. & Vrinda, B. Radiation protection
of human lymphocyte chromosomes in vitro by
orientin  and vicenin. Mutatation  Research, 2001,
498, 39-46.
4 2 2
96. Judy, K.D.; Olivi, A. & Buahin, K.G. Effectiveness
of controlled release of cyclophosphamide
derivative with polymers against rat gliomas.
Journal of Neurosurgery, 1995, 82, 481-86.
97. Menei, P.; Boisdron Selle, M. & Croue, A. Effect
of stereotactic implantation of biodegradable
5-fluorouracil  loaded microspheres in healthy
and C,-glioma-bearing  rats. Neurosurgery, 1996,
36, 117-24.
98. Malaker,  K.; Hodson,  D. & Hadzie, E. Management
of radiation oesophagitis with gaviscon. J. Clin.
Invest., 1988, 11 (suppl 4),  71-76.
99. Vuckovic-Dekic, L.J.; Susnjar, S.; Stanojevic
Bakic, N.; Rajner, L. & Frim, 0. The protective
activity of thymexel against radiotherapeutically-
induced cellular immunodepression in lung cancer
patients. Neoplasma, 1992, 39, 17 l-76.
100.
101.
102.
103,
104.
Garcia, A.H. & Kagiya, V.T. Hypoxia-targeted
radio and chemotherapy for T3-T4  breast cancer
patients without routine mastectomy-six year
results. In gth International Conference on
Chemical Modifiers of Cancer Treatment,
22-26 August1995, Christ Church, Oxford,
UK, 1995.
Malakar, K.; Vijay, K.; Hodson,  I. & Chambers,
M. Radioprotective effect of vitamin E following
radiotherapy for breast cancer. In Annual
Meeting of the Radiation Research Society,
March 20-25, Dallas, 1993.
Glover, D.; Grabelsky, S.; Fox, K.; Weiler,
C.; Cannon, L. & Glick,  J. Clinincal  trials
of WR-2721 and cisplatim. Int. J Radiat.
Oncol. Biol. Phys., 1989, 16, 1201-204.
Marberger, H.; Bartsch, G.; Huber, W.;
Menander, K.B. & Schulte,  T.L. Orgatein:
A new drug for the treatment of radiation
cystitis. Curr. Ther. Res. Clin. Exp., 1975,
18, 466-75.
Word, W.F.; Shih Hoellworth, A. & Johnson,
P.M. Survival of penicillamine treated mice
following wholebody irradiation. Radiation
Research, 1980, 81, 131-37.
UPADHYAY, et  al.: CHEMICAL RADIOPROTECTORS
105.
106.
107.
108.
109.
110.
1 1 1 .
112.
113.
Kuna, P. Radioprotective and heamodynamic
action of cystamine given intramuscularly in
rats. Radiobiology Radiotherapentics, 198 1,
22, 793-800.
Bird, R.P. Cysteamine as a protective agent
with high LET radiations. Radiation Research,
1980, 82, 290-96.
Sweeny, T.R. A survival of compounds from
the antiradiation drug development programme
of the US Army Medical Research and
Development Command, Walter Reed Army
Research Institute, Washington DC, 1982.
359p.
Van der Meer, C. & van Bekkum, D.W. A
study on the mechanism of radiation protection
by 5hydroxytryptamine  & tryptamine. Int.
J. Radiat. Biol., 1961, 4(l), 105-10.
Gupta, M.L.; Singh, R.P. & Uma Devi, U.
Protection of mouse liver by 2-mercapto-
propyonylglycine against fl radiations from
injected tritiated water. J.  Radiat. Res.,
1979, 20, 329-33.
Prasanna, P.G.S. & Uma Devi, P. Modification
of WR 2721 radiation protection from
gastrointestinal injury and death in mice
by 2-mercaptopropyonylglycine.  Radiation
Research, 1993, 133, 111-15.
Garriott, M.L. & Crowe, D.T. AET reduces
the frequency of micronuclei in bone marrow
cells of mice exposed to gamma radiation.
Radiation Research, 1983, 93, 200-04.
Revesz, L.; Bergstrom, H. & Modig, H. Intrinsic
non-protein sulphydryl levels and cellular
radiosensitivity. Nature (London), 1963,198,
1275-277.
Kolman, G.; Shapiro, B.; Leon, S. & Martin,
D. The distribution and metabolism of the
radiation protective agent aminopropylaminoethy1
phosphorothioate (WR-2721) in mice. Report
No AD-070993/l, 1978.
114.
115.
116.
117.
118.
119.
120.
121.
Roots, R. & Okada,  S. Protection of DNA
molecules of cultured mammalian cells from
radiation-induced single strand scission by
various alcohols and -SH compounds. Int.
J. Radiat. Oncol. Biol. Phys.,  1972, 21,
329-42.
Chapman, J.D.; Doern, S.D.; Ravers, A.P.;
Gillespie, C.J.; Chatterjee, A.; Blakely, E.A.;
Smith, K.C. & Tobias, C.A. Radioprotection
by DMSO of mammalian cell exposed to
x-rays and to heavily charged particle beams.
Radiat. Environ. Biophys., 1979, 16, 29-41.
Upadhyay, S.N. Interaction of deoxyribonucleic
acid with &4mino-ethyl  isothiouronium bromide
hydrobromide radiation protection and
environment. Bull. Radiat. Protect., 1998,
21(l),  45-53.
Upadhyay, S.N. Interaction P-amino-ethyl
isothiouronium bromide hydrobromide with
the bases of DNA, basic amino-acids and
nucleohistone. J. Surface Sci. & Technol.,
1999, 15(3-4)  137-46.
Alexander, P.; Dean, C.J.; Lehmann, A.R.;
Ormerod, M.G.; Felds-criber, P. & Serianni,
R.W. In Radiation protection and sensitisation,
edited by H.L. Moroson and M. Quintilliani.
Barnes & Noble, New York, 1970. pp. 15-34.
Renson, J. Radioprotection de la souris  par
la 5-hydoxy-L-tryptamine  et quelques substances
voisines. Arch. Intern. Physiolog. Biochemie.,
1960, 68, 531-37 (French).
Bloomberg, A.L.; Nelson, D.F.N.; Gramkowski,
M.; Glover, D.; Glice,  G.A.; Yuhas, J.M. &
Kligerman, M.M. Clinical trials of WR-272 1
with radiation therapy. Int. J. Radiat. Oncol.
Biol. Phys., 1985, 8, 561-63.
Bogo, V.; Jacob, A.J. & Weiss, A.J.
Behavioural toxicity and efficacy of WR-272 1
as radioprotector. Radiation Research,
1985,104, 182-90.
423
DEF SC1  J. VOL. 55, NO. 4, OCTOBER 2005
122.
123.
124.
125.
126.
127.
128.
129.
Saini, SK.; Dey, J.; Dey, T.B.; Sharma, A.K.;
Ganguly, S.K.; Upadhyay, S.N. & Khanna,
C.M. A preliminary combined regimen study
of some radioprotectors with a lethal dose
of gamma radiation. Ind. J. Nucl.  Medi.,
1994, 19(4),  246-50.
Booth, V.K.; Roberts, J.C.; Warters, R.C.;
Wilmore, B.H. & Lepock, J.R. Radioprotective
thiolamines WR- 1065 and WR-33278
selectively denature nonhistone nuclear
proteins. Radiation Research, 2000, 153,
813-22.
Yuhas, J.M. & Storer, J.B. Differential
chemoprotection of normal and malignant
tissues. J. Natl. Cancer Inst., 1969,42,621-28.
Malick,  M.A.; Roy, R.M. & Sternberg, J.
Effect of vitamin E on post-irradiation death
in mice. Experentia, 1978, 34, 1216-217.
Srinivasan, V. & Weiss, J.F. Radioprotection
by vitamin E: Injectable vitamin E administered
alone or with WR-3684 enhances survival
of irradiated mice. Int. J. Radiat. Oncol.
Biol. Phys., 1992, 23, 841-45.
Ainswoth, E.J. From endotoxin to newer
immunomodulators: Survival promoting effects
of microbial polysaccharides complexes in
irradiated mice. Pharmacological Therapy,
1988, 39, 223-25.
Neta,  R. Role of cytokines in radioprotection.
Pharmacological Therapy, 1988, 39, 261-66.
Casterlli, M.P.; Black, P.L. & Schneider, M.
Protective, restorative and therapeutic properties
130.
131.
132.
133.
134.
135.
of recombinant human IL 1 in rodent models.
Journal of Immunology, 1988, 140, 3830-
833.
Ghose, A.; Ganguly, S.K.; Dey, J. & Mathur,
M. Radioprotectors to mice by combination
of hydroxytryptophan with AET or MPG.
Bone marrow histology study. Radiobiologya
Radiotherapia, 1987, 28, 477-82.
Basu, S.K.; Srinivasan, M.N.; Chuttani, K.
& Ghose, A. Evaluation of some radioprotectors
by the survival study of rats exposed to lethal
dose of wholebody gamma irradiation. J.  Radiat.
Res., 1985, 26, 395-03.
Basu, S.K.; Srinivasan, M.N.; Chuttani, K.;
Bhatnagar, A.; Ghose, A. & Chandra, K.
Rat tissue GSH level and glutathione reductase
activity in radiopotected rats. Bull. Radiat.
Protect.,  1986, 9, 185-88.
Srinivasan, M.N.; Basu, S.K.; & Ghose, A.
Evaluation of radioprotectors by the Na’  influx
study in RBC of lethally irradiated rats.
Strahlentherapie, 1984, 160, 565-66.
Srinivasan, M.N. & Basu, S.K. Effect of
radioprotectors on the altered DNA content
in rats tissues following wholebody gamma
irradiation. Radiobiology Radiotherapy, 1988,
29, 421-27.
Srinivasan, M.N.; Sarin, R.C. & Basu, S.K.
Protection to testicular activity by a combination
of 5-hydoxy-L-tryptophan  with a thiol compound
in wholebody gamma irradiated rats. Ind. J.
Exp. Biol., 1989, 27, 640-43.
4 2 4
UPADHYAY, et al.: CHEMICAL RADIOPROTECTORS
Contributor
Dr S.N. Upadhyay did his PhD  from the Jadavpur University in 1971. He joined
DRDO at the Institute of Nuclear Medicine and Allied Sciences and retired as
Senior Scientist. His research areas are: Structure and function of biopolymers
in the unirradiated and irradiated states, chemical, biochemical, and in vitro
biological dosimeters, chemical radioprotectors and their application in civil
and Defence.
425
